KT-333

News alerts, weekly reports and conference planners

Company:

Kymera Therap

Drug class:

STAT3 protein degrader

Related drugs:

‹

›

No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	KT-333 Sensitive: B - Late Trials GlobeNewswire - 5 days (New B) KT-333 Sensitive : B GlobeNewswire - 5d	KT-333 Sensitive: B - Late Trials GlobeNewswire - 5 days KT-333 Sensitive : B GlobeNewswire - 5 days - (New B)
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	KT-333 Sensitive: B - Late Trials GlobeNewswire - 5 days (New B) KT-333 Sensitive : B GlobeNewswire - 5d	KT-333 Sensitive: B - Late Trials GlobeNewswire - 5 days KT-333 Sensitive : B GlobeNewswire - 5 days - (New B)

Associations
(2)